Skip to main content
Premium Trial:

Request an Annual Quote

NephroSant Raises $16M in Series A Funding Round

NEW YORK – NephroSant said on Tuesday that it has closed an oversubscribed $16 million Series A funding round.

The financing round was led by DaVita, with participation from DigitalDx Ventures and other previous investors.

The San Francisco-based startup will use the funds to support research and development and to launch its Qsant urine test to help determine if a patient's body is rejecting a kidney transplant.

The Qsant assay analyzes six biomarkers from a patient's urine sample, including the amount of cell-free DNA (cfDNA), the fraction of methylated cfDNA, the proteins clusterin and creatinine, the inflammation marker CXCL10, and total protein amount in the urine. The test provides a threshold score — called a "Q-Score" — and a numerical score for the intensity of the rejection.  

"[DaVita's] expertise and experience provide the perfect complement to the vision and focus of NephroSant to redefine kidney health," Minnie Sarwal, CEO and founder, said in a statement.

"Transforming kidney care requires bold innovation, which is precisely why DaVita Venture Group invested in NephroSant and its game-changing solution that helps patients manage their transplanted kidney health," Jeff Giullian, chief medical officer of DaVita, said in a statement. "As a transplant nephrologist, I look forward to a future where patients not only have greater access to a transplant but also can extend the life of a transplant with Qsant."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.